New cancer drug combo tested in early trial

NCT ID NCT06487858

First seen Dec 15, 2025 · Last updated May 11, 2026 · Updated 21 times

Summary

This early-stage study tested a new experimental drug called BGB-R046, given alone or with another drug (tislelizumab), in 42 people with advanced or spreading solid tumors that had not responded to standard treatments. The main goals were to check safety, find the best dose, and see if the drug shrinks tumors. The study was terminated early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Fujian Cancer Hospital

    Fuzhou, Fujian, 350014, China

  • Guangxi Medical University Cancer Hospital

    Nanning, Guangxi, 530021, China

  • Jinan Central Hospital

    Jinan, Shandong, 250013, China

  • Jining No1 Peoples Hospital West Branch

    Jining, Shandong, 272000, China

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, 200433, China

  • The First Hospital of China Medical University

    Shenyang, Liaoning, 110001, China

  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, 430022, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, 610041, China

Conditions

Explore the condition pages connected to this study.